IGF1R and hepatocellular carcinoma: Notably, a combination of niclosamide and sorafenib treatment drastically and significantly suppressed the sorafenib-induced p-IGF-1R intensity of sorafenib-resistant HCC cells under IGF-1 treatment (Lanes 7–10 vs. Lane 2).